Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Fabrizio Stocchi »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Fabrice Poupon < Fabrizio Stocchi < Fabrizzio Stocchi  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
000087 (2013) Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000141 (2011) Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ray K. Chaudhuri [Royaume-Uni] ; Marcelo Merello [Argentine] ; Robert Hauser [États-Unis] ; Regina Katzenschlager [Autriche] ; Per Odin [Allemagne] ; Mark Stacy [États-Unis] ; Fabrizio Stocchi [Italie] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Wearing‐off scales in Parkinson's disease: Critique and recommendations
000198 (2010) Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study
000231 (2009) Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]Validation of the freezing of gait questionnaire in patients with Parkinson's disease
000267 (2009) Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni]Adherence to antiparkinson medication in a multicenter European study
000308 (2008) C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
000432 (2004) C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie]Levodopa in the treatment of Parkinson's disease: Current controversies

List of associated KwdEn.i

Nombre de
documents
Descripteur
7Humans
7Parkinson Disease (drug therapy)
6Nervous system diseases
6Parkinson disease
6Parkinson's disease
5Aged
5Antiparkinson Agents (adverse effects)
5Antiparkinson Agents (therapeutic use)
5Female
5Male
5Middle Aged
4Double-Blind Method
3Dose-Response Relationship, Drug
3Levodopa (adverse effects)
3Severity of Illness Index
3Treatment Outcome
2Adult
2Dyskinesia, Drug-Induced (etiology)
2Indans (therapeutic use)
2Neuroprotective Agents (therapeutic use)
2Parkinson Disease (physiopathology)
2Placebo
2Psychiatric Status Rating Scales
2Rasagiline
2Treatment
2dyskinesia
2rasagiline
1AMPA receptor
1AMPA receptor antagonist
1Advanced stage
1Aged, 80 and over
1Analysis of Variance
1Antiparkinson Agents (pharmacokinetics)
1Catechols (therapeutic use)
1Chemotherapy
1Cognition Disorders (drug therapy)
1Cognition Disorders (etiology)
1Corpus Striatum (drug effects)
1Corpus Striatum (metabolism)
1Dopamine Agents (adverse effects)
1Drug Administration Schedule
1Drug Prescriptions
1Dyskinesia
1Dyskinesia, Drug-Induced (drug therapy)
1Europe (epidemiology)
1Fluctuations
1Follow-Up Studies
1Freezing
1Freezing Reaction, Cataleptic (drug effects)
1Freezing Reaction, Cataleptic (physiology)
1Gait Disorders, Neurologic (chemically induced)
1Gait Disorders, Neurologic (diagnosis)
1Gait Disorders, Neurologic (drug therapy)
1Gait Disorders, Neurologic (physiopathology)
1Human
1Indoles (therapeutic use)
1International Cooperation
1Levodopa
1Levodopa (pharmacokinetics)
1Levodopa (therapeutic use)
1Medication Adherence (psychology)
1Medication Adherence (statistics & numerical data)
1Modification
1Multicenter study
1Nitriles (therapeutic use)
1Outcome Assessment (Health Care)
1Parkinson Disease (complications)
1Parkinson Disease (diagnosis)
1Parkinson Disease (psychology)
1Perampanel
1Principal Component Analysis
1Psychometrics
1Pyridones (therapeutic use)
1Questionnaire
1Questionnaires
1Questionnaires (standards)
1Receptors, AMPA (antagonists & inhibitors)
1Receptors, Dopamine (drug effects)
1Receptors, Dopamine (metabolism)
1Recommendation
1Reliability
1Reproducibility of Results
1Retrospective Studies
1Safety
1Statistics as Topic
1Statistics, Nonparametric
1Time Factors
1Validation
1Validity
1Weights and Measures (standards)
1clinimetrics
1delayed start design
1disease modification
1freezing of gait
1levodopa
1motor complications
1motor fluctuations
1neuroprotection
1neurotoxicity
1perampanel

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Fabrizio Stocchi" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Fabrizio Stocchi" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Fabrizio Stocchi
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024